NasalCEASE - Stop Nosebleeds!

NasalCEASE - Stop Nosebleeds!

The medical term for nosebleed is epistaxis. The origin of epistaxis is Greek, meaning a dropping.

People suffering from minor recurring nosebleeds, represent by far the largest epistaxis patient population, yet the physician has long lacked an effective, safe and convenient self-treatment recommendation for these patients.

A quantitative market survey of 4500+ US households, conducted in 2003 by Harris Interactive Inc., revealed the following:

• 30% of US households have an average of 1.4 sufferers
• The average sufferer experiences 8.75 nosebleeds per year
• Prevalence in the US is 45.1 million sufferers or 15.8% of population
• The result is 395 million minor nosebleeds per year

Until now the market has lacked a safe, effective and convenient treatment for minor nosebleeds:

• 90%+ of sufferers use tissues and/or cotton balls
• These products don't adsorb the blood
• They stick to newly forming clots, causing rebleeding 10% to 15% of the time when removed
• These products require constant manipulation and/or changing drawing more attention to a traumatic, embarrassing event

Minor nosebleeds impact all ages and have several causes. Minor recurring nosebleeds impact all ages from very young children to senior citizens. These nosebleeds are commonly caused by excessive dryness to the nasal mucosa from in-home or external dryness, use of medications such as those to treat allergies, anticoagulation medications, excess trauma to the nasal cavity and blood vessel disorders such as HHT. A minor nosebleed lasts an average of five to ten minutes and typically results in a minimal loss of blood.

The lack of an effective, easy to use self treatment for minor nosebleeds has left both sufferers and physicians frustrated.

What is NasalCEASE?

NasalCEASE is the first FDA approved OTC treatment for nosebleeds (epistaxis).

NasalCEASE is a bio-polymer, derived from a natural molecule, designed and manufactured with the unique properties for the treatment of minor nosebleeds. The key properties of NasalCEASE are:

• Stops Bleeding Quickly
• Adsorbs Blood
• Gelifies For Easy Safe Removal
• Natural Molecule
• NasalCEASE is specifically designed for minor nosebleeds.

NasalCEASE is derived from a natural molecule and has been specifically designed to quickly and conveniently stop minor nosebleeds. The unique properties of NasalCEASE actively provide for rapid cessation of the bleeding. The product releases calcium, which actively enhances the coagulation process, while the material fills the nasal cavity providing mechanical hemostasis. It is highly adsorptive, adsorbing the blood without manipulation or change. As NasalCEASE adsorbs blood, the sodium from the blood causes the material to gelify and become moist. It is this moist state that keeps NasalCEASE from sticking to newly formed clots, allowing for easy removal, without causing rebleeding or pain for the patient. The sufferer can easily and painlessly insert NasalCEASE when a nosebleed occurs and without further fuss, simply remove it within thirty minutes. NasalCEASE's uniquely designed fibers are soft and gentle on the nasal mucosa.

NasalCEASE has been proven safe and effective.
While new to the US, NasalCEASE has been sold over-the-counter in European pharmacies for years. Millions of units are sold annually OTC without any reported adverse reactions. Each NasalCEASE unit is packed in an individual sterile pouch with a five year shelf life. NasalCEASE is sold in boxes of five individual sterile pouches. One sterile pouch is good for one minor nosebleed.

ENT Journal article points to a large unsatisfied market for minor recurring nosebleeds.
In a recent article in a leading ENT Journal entitled, "Minor Recurrent Epistaxis: Prevalence and a new method for management", doctors point to a large unsatisfied market for minor recurring nosebleeds and discuss their experience with use of NasalCEASE in their clinics. Co-authored by two well known ENT's, Dr. Michael Benninger of Henry Ford Hospital and Dr. Brad Marple of University of Texas-Southwestern Hospital, the article was published in the September, 2004 issue of Otolaryngology - Head & Neck Surgery.